• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Annexon, Inc. - common stock (NQ:ANNX)

5.365 +0.005 (+0.09%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 25, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Annexon, Inc. - common stock

< Previous 1 2 3 4 Next >
News headline image
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
March 16, 2026
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Biosciences to Present at the TD Cowen 46th Annual Health Care Conference
February 24, 2026
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon to Host In-Person and Virtual KOL Event to Discuss Vonaprument for the Treatment of Geographic Atrophy
February 17, 2026
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
January 16, 2026
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Accelerating Next Generation Targeted Immunotherapy Platform for Treatment of Neuroinflammatory Diseases with Multiple Registrational Milestones in 2026
January 12, 2026
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Submits Tanruprubart Marketing Authorization Application to the European Medicines Agency for Guillain-Barré Syndrome
January 08, 2026
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 07, 2026
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
December 16, 2025
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $86.25 Million
November 14, 2025
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants
November 12, 2025
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
November 12, 2025
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Reports Third Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones
November 10, 2025
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Biosciences to Participate in Upcoming September Investor Conferences
August 27, 2025
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
August 18, 2025
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Reports Second Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones
August 14, 2025
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Selected by EMA to Participate in Product Development Coordinator Pilot for Vonaprument (ANX007) for Dry Age-Related Macular Degeneration with Geographic Atrophy
August 07, 2025
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Announces Completion of Enrollment in Pivotal Phase 3 ARCHER II Trial of Vonaprument (formerly ANX007) for Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy
July 24, 2025
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Bolsters Ophthalmology Expertise with Appointment of Retina Specialist Lloyd Clark, M.D., as Pivotal ANX007 Program Advances in Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy (GA)
June 18, 2025
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Biosciences to Present at the Jefferies Global Healthcare Conference
May 29, 2025
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Showcases Tanruprubart Data Demonstrating Improved Clinical Outcomes in Guillain-Barré Syndrome (GBS) at 2025 Peripheral Nerve Society (PNS) Annual Meeting
May 19, 2025
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
May 16, 2025
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Reports First Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones
May 12, 2025
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Announces Presentations on the Clinical Advancement of Tanruprubart as the First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) at the 2025 PNS Meeting
May 09, 2025
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon to Present on the Neuroprotective Effects of ANX007 at the 2025 ARVO Annual Meeting and the Retina World Congress
May 07, 2025
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
April 16, 2025
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Highlights Pivotal Data on First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) and Showcases New GBS Education Campaign at American Academy of Neurology (AAN) 2025 Annual Meeting
April 08, 2025
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Highlights Leadership in Advancing Clinical Research and Education for Guillain-Barré Syndrome (GBS) at American Academy of Neurology (AAN) 2025 Annual Meeting
April 03, 2025
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
March 17, 2025
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Reports Fourth Quarter and Year-End 2024 Financial Results, Portfolio Progress and Key Anticipated Milestones
March 03, 2025
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Biosciences to Present at the TD Cowen 45th Annual Health Care Conference
February 26, 2025
From Annexon Biosciences
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap